• 1
    Sanchez-Tapias JM. Viral hepatitis C. In: PrietoJ, RodesJ, ShafritzDA, eds. Hepatobiliary Diseases. Berlin: Springer-Verlag, 1992; 573610.
  • 2
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 312: 15061510.
  • 3
    Lau JYN, Mikozami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-a in chronic hepatitis C. Lancet 1993; 342: 12081209.
  • 4
    Saracco G, Rossina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow up of patients with chronic hepatitis C treated with different doses of interferon-α2b. Hepatology 1993; 18: 13001305.
  • 5
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis C treated with a-interferon. Hepatology 1992; 15: 10131016.
  • 6
    Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 65476549.
  • 7
    Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, De-Alava E, Civeira MP, Castilla A, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994; 21: 411.
  • 8
    Del Val M, Schlicht H-J, Volkmer H, Messerle M, Reddehase MJ, Koszi-nowski UH. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nanomeric T-cell epitope. J Virol 1991; 65: 36413646.
  • 9
    Kast WM, Roux L, Curren J, Blom HJJ, Voordouw AC, Meloen RH, Kola-kofsky D, et al. Protection against lethal Sendai virus infection by in vivo priming of virus specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A 1991; 88: 22832287.
  • 10
    Klavinskis LS, Whitton JL, Oldstone MBA. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confers protection from lethal virus infection. J Virol 1989; 63: 43114316.
  • 11
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238241.
  • 12
    Schulz M, Zinkernagel RM, Hengartner H. Peptide induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci U S A 1991; 88: 991993.
  • 13
    Watari E, Dietzschold B, Szokan G, Herber-Katz E. Synthetic peptide induces long term protection from lethal infection with herpes simplex virus 2. J Exp Med 1987; 165: 459470.
  • 14
    Yap KL, Ada GL, McKenzie IFC. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978; 273: 238239.
  • 15
    Zinkernagel RM, Doherty PC. MHC restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determines T cell restriction-specificity function and responsiveness. Adv Im-munol 1979; 27: 52142.
  • 16
    Shirai M, Akatsuka T, Pendelton CD, Houghten R, Wychowski C, Mihalik K, Feinstone SM, et al. Induction of cytotoxic T cells to a cross reactive epitope in the hepatitis C virus non-structural RNA polymer as e-like protein. J Virol 1992; 66: 40984106.
  • 17
    Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, Pendelton CD, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 33343342.
  • 18
    Shirai M, Arichi T, Nishioka M, Nomura T, Ikeda K, Kawanishi K, Engelhard VH, et al. CTL responses of HLA.A2.1 transgenic mice specific for hepatitis C viral peptides predicts epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995; 154: 27332742.
  • 19
    Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252: 16621667.
  • 20
    Welsh MJ, Zabner J, Graham SM, Smith AE, Moscicki R, Wadsworth S. Adenovirus-mediated gene transfer for cystic fibrosis: part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum Gene Ther 1995; 6: 205218.
  • 21
    Jacobs SC, Stephenson JR, Wilkinson GWG. High level expression of the Tick-borne encephalitis virus NS1 protein using an adenovirus based vector: protection elicited in a murine model. J Virol 1992; 66: 20862095.
  • 22
    Wilkinson GWG, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 1992; 20: 22332239.
  • 23
    Graham FL, Smiley J, Russell WL, Nairm R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 5972.
  • 24
    McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 1988; 163: 614617.
  • 25
    Graham FL, Van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456467.
  • 26
    Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetra-peptide. J Am Chem Soc 1963; 85: 21492154.
  • 27
    Atherton E, Logan JC, Sheppard RC. Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenyl methoxycarbonyl aminoacids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65–74 decapeptide. Journal of Chemical Society Perkins Transactions 1989; 1: 538546.
  • 28
    Borrás-Cuesta F, Golvano J, Sarobe P, Lasarte JJ, Prieto I, Szabo A, Guillaume JL, et al. Insights on the amino acid side chain interaction of a synthetic T-cell determinant. Biologicals 1991; 19: 187190.
  • 29
    Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro: inhibition by isoantibody and by drugs. Immunology 1968; 14: 181196.
  • 30
    Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993; 67: 67536761.
  • 31
    Grakoui A, Wychowsky C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 13851395.
  • 32
    Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rize CM. Formation and intracellular location of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994; 68: 61476160.
  • 33
    Lo SY, Selby M, Tong M, Ou JH. Comparative studies of the core gene products of two different hepatitis C virus isolates: two alternative forms determined by a single amino acid substitution. Virology 1994; 199: 124131.
  • 34
    Cerny A, McHutchinson JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521530.
  • 35
    Koziel MJ, Dudley D, Afdhal N, Choo Q-L, Houghton M, Ralston R, Walker B. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 75227532.
  • 36
    Battegay M, Fikes J, Di Bisceglie AD, Wentworth PA, Sette A, Celis E, Ching W-M, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA.A2.1 molecules. J Virol 1995; 69: 24622470.
  • 37
    Hosmalin A, Clerici M, Houghten R, Pendleton CD, Flexner C, Lucey DR, Moss B, et al. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1990; 87: 23442348.
  • 38
    Mizuochi T, Hugin AW, Morse III HC, Singer A, Buller RML. Role of lymphokine-secret ing CD8+ T cells in cytotoxic T lymphocyte responses against vaccinia virus. J Immunol 1989; 142: 270273.
  • 39
    Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992; 257: 927930.
  • 40
    Rötzschke O, Falk K, Deres K, Shild H, Norda N, Metzger J, Jung G, et al. Isolation and analysis of naturally processed viral peptides as recognised by cytotoxic T cells. Nature 1990; 348: 252254.
  • 41
    Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci U S A 1993; 90: 82348238.
  • 42
    Diepolder HM, Zachoval R, Hoffman RM, Wierenga EA, Sanantonio T, Jungand M-C, Eichenlaub D, et al. Possible mechanism involving T-lym-phocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 10061007.
  • 43
    Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, Slaoui M, et al. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Thl+ T cells. J Virol 1995; 69: 47114716.
  • 44
    Fooks AR, Schadeck E, Liebert UG, Dowsett AB, Rima BK, Steward M, Stephenson JR, et al. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-I restricted CTL response and protection in a murine model. Virology 1995; 210: 456465.
  • 45
    Gallicham WS, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J Infect Dis 1993; 168: 622629.
  • 46
    Jacobs SC, Stephenson JR, Wilkinson GWG. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Gen Virol 1994; 75: 23992402.
  • 47
    Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, Molnar-Kimber K, Mason BB, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 1989; 86: 67636767.
  • 48
    Prevec L, Campbell JB, Christie BS, Belbeck L, Graham FL. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990; 161: 2730.
  • 49
    Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, Saito Y. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996; 14: 2834.
  • 50
    Falk K, Roetzschke O, Stevanovic S, Jung G, Ramensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290292.
  • 51
    Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, Choo Q-L, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: 580587.
  • 52
    Choo Q-L, Kuo G, Ralstone R, Weiner A, Chien D, Van Nest G, Han J, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91: 12941298.
  • 53
    Sarobe P, Jauregui JI, Lasarte JJ, Garcia N, Civeira MP, Borras-Cuesta F, Prieto J. Production of IL-2 in response to synthetic peptides from hepatitis C virus El protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J Hepatol 1996; 25: 19.
  • 54
    Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigen limits E 1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 44074411.
  • 55
    Yang Y, Xiang Z, Ertl HC, Wilson JM. Upregulation of class I major histo-compatibility complex antigens by interferon gamma is necesary for T cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995; 92: 72577261.
  • 56
    Franco A, Ferrari C, Sette A, Chisari FV. Viral mutations, TCR antagonism and escape from the immune response. Curr Opin Immunol 1995; 7: 524531.
  • 57
    Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV- l)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection; differential CTL responses to HIV and Epstein-Barr virus in late disease. J Exp Med 1993; 177: 249256.
  • 58
    Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JGP. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia virus. J Exp Med 1988; 168: 919931.
  • 59
    Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92: 27552759.